Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 548-557

  Lee, Chung Soo ^a   Jang, Eun Ra ^a   Kim, Yun Jeong ^a   Myung, Soon Chul ^b   Kim, Wonyong ^a   Lee, Min Won ^a  

^a Chung Ang University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

Apoptosis related proteins; Epithelial ovarian adenocarcinoma cell lines; Hirsutenone; Synergistic effect; TRAIL

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH RECEPTOR; HEPTANE DERIVATIVE; HIRSUTENONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CATECHOL DERIVATIVE; RECOMBINANT PROTEIN; TNFSF10 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN SECRETION; WESTERN BLOTTING; CELL SURVIVAL; DNA DAMAGE; DOSE RESPONSE; DRUG POTENTIATION; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CATECHOLS; CELL LINE, TUMOR; CELL SURVIVAL; DIARYLHEPTANOIDS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECEPTORS, DEATH DOMAIN; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84862289734     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9601-5     Document Type: Article

References (28)

1. Armstrong JS (2006) Mitochondria: a target for cancer therapy. Br J Pharmacol 147(3):239-248. doi:10.1038/sj.bjp.0706556
2. Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4(12):721-729. doi:10.1016/S1470-2045(03)01277-4
3. Mahmood Z, Shukla Y (2010) Death receptors: targets for cancer therapy. Exp Cell Res 316(6):887-899. doi:10.1016/j.yexcr. 2009.12.011
4. Wu GS (2009) TRAIL as a target in anti-cancer therapy. Cancer Lett 285(1):1-5. doi:10.1016/j.canlet.2009.02.029
5. MacFarlane M (2003) TRAIL-induced signaling and apoptosis. Toxicol Lett 139(2-3):89-97. doi:10.016/S0378-4274(02)00422-8
6. Jin Z, El-Deiry WS (2005) Overview of cell death signaling pathways. Cancer Biol Ther 4(2):139-163. doi:10.4161/cbt.4.2.1508
7. Kuroyanagi M, Shimomae M, Nagashima Y, Muto N, Okuda T, Kawahara N, Nakane T, Sano T (2005) New diarylheptanoids from Alnus japonica and their antioxidative activity. Chem Pharma Bull Tokyo 53(12):1519-1523. doi:10.1248/cpb.53.1519
8. Lee MW, Kim NY, Park MS, Ahn KH, Toh SH, Hahn DR, Kim YC, Chung HT (2000) Diarylheptanoids with in vitro inducible nitric oxide synthesis inhibitory activity from Alnus hirsuta. Planta Med 66(6):551-553. doi:10.1055/s-2000-8606
9. Lee SL, Huang WJ, Lin WW, Lee SS, Chen CH (2005) Preparation and anti-inflammatory activities of diarylheptanoid and diarylheptylamine analogs. Bioorg Med Chem 13(22):6175-6181. doi:10.1016/j.bmc.2005.06.058
10. Choi SE, Kim KH, Kwon JH, Kim SB, Kim HW, Lee MW (2008) Cytotoxic activities of diarylheptanoids from Alnus japonica. Arch Pharm Res 31(10):1287-1289. doi:10.1007/s12272-001-2108-z
11. Jin W, Cai XF, Na M, Lee JJ, Bae K (2007) Diarylheptanoids from Alnus hirsuta inhibit the NF-κB activation and NO and TNF-α production. Biol Pharm Bull 30(4):810-813. doi:10.1248/bpb.30.810
12. Joo SS, Kim MS, Oh WS, Lee DI (2002) Enhancement of NK cytotoxicity, antimetastasis and elongation effect of survival time in B16-F10 melanoma cells by oregonin. Arch Pharm Res 25 (4):493-499
13. Lee CS, Jang ER, Kim YJ, Lee MS, Seo SJ, Lee MW (2010) Hirsutenone inhibits lipopolysaccharide-activated NF-κB-induced inflammatory mediator production by suppressing Toll-like receptor 4 and ERK activation. Int Immunopharmacol 10 (4):520-525. doi:10.1016/j.intimp.2010.01.015
14. Lee CS, Ko HH, Seo SJ, Choi YW, Lee MW, Myung SC, Bang H (2009) Diarylheptanoid hirsutenone prevents tumor necrosis factor-α-stimulated production of inflammatory mediators in human keratinocytes through NF-κB inhibition. Int Immunopharmacol 9(9):1097-1104. doi:10.1016/j.intimp.2009.05.006
15. Kim JH, Lee KW, Lee MW, Lee HJ, Kim SH, Surh YJ (2006) Hirsutenone inhibits phorbol ester-induced upregulation of COX-2 and MMP-9 in cultured human epithelial cells: NFκB as a potential molecular target. FEBS Lett 580(2):385-392. doi:10.1016/j.febslet.2005.12.015
16. Högberg T, Glimelius B, Nygren P (2001) A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 40(2-3):340-360
17. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65(1-2):55-63. doi:10.1016/0022-1759(83)90303-4
18. Andrisano V, Ballardini R, Hrelia P, Cameli N, Tosti A, Gotti R, Cavrini V (2001) Studies on the photostability and in vitro phototoxicity of Labetalol. Eur J Pharm Sci 12(4):495-504. doi:10.1016/S0928-0987(00)00218-9
19. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, Schulte-Hermann R (1992) Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor 1. Proc Natl Acad Sci USA 89(12):5408-5412
20. Berthier A, Lemaire-Ewing S, Prunet C, Monier S, Athias A, Bessede G, Pais de Barros JP, Laubriet A, Gambert P, Lizard G, Néel D (2004) Involvement of a calcium-dependent dephosphorylation of BAD associated with the localization of Trpc-1 within lipid rafts in 7-ketocholesterol-induced THP-1 cell apoptosis. Cell Death Differ 11 (8):897-905. doi:10.1038/sj.cdd.4401434
21. Chipuk JE, Green DR (2006) Dissecting p53-dependent apoptosis. Cell Death Differ 13(6):994-1002. doi:10.1038/sj.cdd.4401908
22. Camins A, Pallas M, Silvestre JS (2008) Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Meth Fin Exp Clin Pharmacol 30(1):43-65. doi:10.1358/mf.2008.30.1.1090962
23. Czabotar PE, Colman PM, Huang DC (2009) Bax activation by Bim? Cell Death Differ 16(9):1187-1191. doi:10.1038/cdd.2009.83
24. Kim R, Emi M, Tanabe K (2006) Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 57(5):545-553. doi:10.1007/s00280-005-0111-7
25. Borutaite V (2010) Mitochondria as decision-makers in cell death. Environ Mol Mutagen 51:406-416. doi:10.1002/em.20564
26. Wiman KG (2006) Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13(6):921-926. doi:10.1038/sj.cdd.4401921
27. Chen F, Wang W, El-Deiry WS (2010) Current strategies to target p53 in cancer. Biochem Pharmacol 80:724-730. doi:10.1016/j.bcp.2010.04.031
28. Zhivotovsky B, Orrenius S (2010) Cell death mechanisms: crosstalk and role in disease. Exp Cell Res 316(8):1374-1383. doi:10.1016/j.yexcr.2010.02.037